Powder Systems (PSL) has signed a licence agreement with Ashe Morris (AML) to develop and supply a range of reactors and bioreactors incorporating the patented Constant Flux Technology. Fitting in with the FDA's PAT (Process Analytical Technology) initiative, Constant Flux (COFLUX) Technology has the potential to help reduce drug development times by up to 6 months.
The technology uses on-line reaction monitoring (via calorimetry) to provide valuable insight into process specifics, improving yields and end point detection by monitoring the on-line rate of reaction of virtually any chemical, physical or biological process. The range of COFLUX chemical reactors and bio-reactors will be ready for market later this year following the completion of a programme of co-development between PSL and AML.
'This collaboration demonstrates our commitment to providing total process solutions to the drug development and production industry, and to expanding our portfolio of containment and process capabilities,' said Gary Howse, director, PSL.
